Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors.

ABSTRACT:

Background

Little is known about the initiation of alcohol use disorder (AUD) treatments among cancer survivors, despite the unique harms that unhealthy alcohol use may have on this population. We assessed patterns, timing, and predictors of AUD treatment among cancer survivors.

Methods

We used commercial claims data on US adult cancer survivors from 2011 to 2021 in this retrospective cohort study. We included individuals with a new AUD diagnosis and continuous insurance enrollment. We measured initiation and timing of Food and Drug Administration (FDA)-approved (naltrexone, acamprosate, and disulfiram), non-FDA-approved (gabapentin, topiramate, and baclofen), and investigational (ondansetron and varenicline) medications for AUD (MAUDs), psychosocial therapies, and rehabilit

SUBMITTER: Lai JH 

PROVIDER: S-EPMC12617484 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature